Minervax is a company that develops a vaccine candidate against group B streptococci (GBS). Its vaccine targets pregnant women for the prevention of life-threatening bacterial infections in newborns. The company's platform technology is based on the combination of immunogenic and protective protein domains from two surface proteins of GBS (N-terminals of AlphaC and Rib, GBS-NN).